|1.||Bessler, Wolfgang G: 2 articles (01/2010 - 01/2009)|
|2.||vor dem Esche, Ulrich: 2 articles (01/2010 - 01/2009)|
|3.||Bessler, W G: 2 articles (12/2000 - 03/2000)|
|4.||Huber, M: 2 articles (12/2000 - 03/2000)|
|5.||Geerlings, S E: 1 article (12/2013)|
|6.||van Charante, N Mensing: 1 article (12/2013)|
|7.||ter Riet, G: 1 article (12/2013)|
|8.||Beerepoot, M A J: 1 article (12/2013)|
|9.||van Haarst, E P: 1 article (12/2013)|
|10.||Zgaga-Griesz, Andrea: 1 article (01/2010)|
01/01/1989 - "A significant improvement was observed in the OM-8980 group in comparison with the placebo group as regards the Ritchie index (P = 0.002), grip strength (P = 0.02) and pain (P = 0.03). "
01/01/1989 - "Ritchie index, number of swollen joints and the pain scale improved significantly more with OM-8980 than with placebo. "
09/01/1990 - "At the end of this second phase, the Ritchie index, number of swollen joints, pain scale, morning stiffness, grip strength and ESR had all improved further with respect to the significant improvements already recorded under OM-8980 and auranofin in the double-blind phase. "
01/01/1990 - "After 12 months of treatment, the parameters of Ritchie index, duration of morning stiffness, pain assessed by a visual analogue scale and categories, number of swollen joints, grip strength and erythrocyte sedimentation rate (ESR) were all significantly improved with OM-8980, as was the case for the Ritchie index, number of swollen joints and ESR with D-penicillamine. "
01/01/1990 - "Significant intergroup differences were recorded for pain categories in favour of OM-8980 and for the Ritchie index and number of swollen joints in favour of D-penicillamine. "
12/01/1991 - "OM-8980 is an immunomodulating drug which has been shown in double blind placebo controlled trials to be effective in the management of rheumatoid arthritis (RA). "
08/01/1993 - "A 6-month randomized dose range study of OM-8980 in rheumatoid arthritis."
01/01/1989 - "A total of 95 patients suffering from active rheumatoid arthritis were included in this double-blind, placebo-controlled study of the immunomodulator OM-8980. "
01/01/1989 - "Double-blind, placebo-controlled study of OM-8980 in rheumatoid arthritis."
01/01/2006 - "However, OM-89 has also shown clear efficacy in patients with rheumatoid arthritis or with undifferentiated spondyloarthropathies, probably through oral tolerance and the long-term activation of regulatory cells. "
|3.||Urinary Tract Infections (Urinary Tract Infection)
01/01/2006 - "OM-89, a lysate of Escherichia coli, is clinically effective in patients who experience recurrent urinary tract infections by activating both innate and adaptive immunity. "
12/01/2013 - "The oral immunostimulant OM-89 decreased the rate of urinary tract infection recurrence (4 trials, sample size 891, median Jadad score 3, RR 0.61, 95% CI 0.48-0.78) and had a good safety profile. "
03/27/2000 - "The bacterial extract OM-89 used for the prevention and treatment of recurrent urinary tract infections constitutes an effective immunostimulant in vitro and in vivo. "
12/01/2000 - "The bacterial extract OM-89 (Uro-Vaxom) consisting of immunostimulating components derived from 18 Escherichia coli strains is used for the treatment of recurrent urinary tract infections. "
01/01/2006 - "An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis."
06/01/1995 - "OM-89 modulation of chronic inflammation: relevance to clinical use."
08/16/1995 - "Alternatively, even if the human hsp65 is not a target molecule in RA joints, OM-89 may evoke bystander suppression of joint inflammation via induction of TGF beta-secreting effector cells. "
10/01/1997 - "Given the evidence that immunity to bacterial heat shock antigens plays a critical role in the immunomodulation of arthritis and possibly inflammation in general, the purpose of the present studies was to evaluate the presence and immunogenicity of hsp in OM-89. "
01/01/1998 - "This may constitute one mode of action for OM-89 as an arthritis suppressive oral drug in man."
10/01/1997 - "This may also constitute a mode of action for OM-89 as an arthritis-suppressive oral drug."
10/01/1997 - "Given the arthritis-inhibitory effect of oral OM-89 in AA, it is possible that peripheral tolerance is induced at the level of regulatory T cells with specificity for hsp. "
12/01/1995 - "Polyarthritis in the rat: effects of tolerance and sensitization to the bacterial extract OM-89 with a possible mode of action."
01/01/1998 - "Parallel to the effects displayed by immunisation with hsp, oral administration of hsp-containing OM-89 was found to modify autoimmune disease in a number of animal models, such as for arthritis, diabetes and SLE. "
|6.||Heat-Shock Proteins (Heat-Shock Protein)
|9.||Transforming Growth Factor beta (TGF-beta)
|10.||Interferon-gamma (Interferon, gamma)
|4.||Drug Therapy (Chemotherapy)